Wednesday, August 20, 2014

Tuesday Features

Titan implanting treatments for opioid dependence

Titan implanting treatments for opioid dependence

In the continuing struggle to circumvent abuse of drugs to treat opioid dependence and enhance compliance regimes for better outcomes, Titan Pharmaceuticals (OTCBB:TTNP) is leading the race with a matchstick-sized implant of the approved drug, buprenorphine, which eases withdrawal symptoms. Sunil Bhonsle “With more than two million people in the U.S.... [Read more of this feature]


Lorus hopes to start LOR-253 trial in mid-September

Lorus hopes to start LOR-253 trial in mid-September

After a corporate refocusing with a new management and clinical development team, Lorus Therapeutics (OTC:LRUSF; TSX:LOR) plans to begin a Phase 1b clinical trial in mid-September of its LOR-253 drug candidate for the treatment of several blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), which is a... [Read more of this feature]


In conversation with Jason Mitakidis

In conversation with Jason Mitakidis

Jason Mitakidis As president and CEO of closely held Cyclica, Jason Mitakidis first became interested in computer simulation or, in silico, drug discovery while he was working as a bioinformatician at the Barcode of Life Project in 2006 and 2007. Prior to co-founding Cyclica in 2011, he gained several years of research experience in the fields of molecular... [Read more of this feature]


More Posts From Tuesday Features

Briefs

Scientific data supports superiority of Pivotal’s Omega-3 product

Scientific data supports superiority of Pivotal’s Omega-3 product

Pivotal Therapeutics (OTCQX:PVTTF; CSE:PVO) has reported that an article published in the current issue of the scientific journal demonstrates that the sustained endothelial vasodilatory effect of Omega-3 formulations are EPA:DHA ratio and purity dependent and involve predominantly the endothelial nitric oxide synthase derived nitric oxide formation. Pivotal’s... [Read more of this brief]


Gamida Cell in investment pact with Novartis

Gamida Cell in investment pact with Novartis

Closely held Gamida Cell of Israel has signed an investment and option agreement with Novartis Pharma AG. Under the accord, Novartis will invest $35-million in Gamida Cell in exchange for a 15% equity interest and an option to fully acquire Gamida Cell. The option is exercisable for a limited period of time following achievement of certain milestones... [Read more of this brief]


Leerink starts Immune Design at outperform

Leerink starts Immune Design at outperform

Leerink Partners has launched coverage of Immune Design (NASDAQ:IMDZ) with an “outperform” rating and 12-month price target of $25. The stock was quoted at $12.15 near the mid-session on Monday. The company is focused on immunotherapies for cancer, and has two proprietary platforms, ZVex and GLAAS, for activating essential cells of the immune system... [Read more of this brief]


Leerink starts Intersect ENT at outperform

Leerink starts Intersect ENT at outperform

Leerink Partners has launched coverage of Intersect ENT (NASDAQ:XENT) with an “outperform” rating and $20 price target. The stock closed at $15.05 on Friday. “Intersect looks set to deliver a 73% 2013-2016 CAGR (at least), faster than most small-cap MedTech peers, as the company drives higher ear, nose and throat (ENT) use of its unique steroid-eluting... [Read more of this brief]


WB starts Pfenex at outperform

WB starts Pfenex at outperform

William Blair & Co. has initiated coverage of Pfenex (NYSE MKT:PFNX) with an “outperform” rating and “aggressive growth” profile. The stock closed at $6.50 on Friday. “Our bullish outlook is based on our view that the combination of the company’s lead product candidate, technology platform, advancing pipeline, and potential for additional... [Read more of this brief]


More Posts From Briefs
Email Newsletters with Constant Contact
Google+